BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq ... led to the FDA approval of Cobenfy™ (formerly KarXT) for schizophrenia. With Glyph, we believe each of Seaport’s programs could ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today ...

(Alliance News) - PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia.

PureTech Systems Inc. is proud to announce the release of PureActiv Version 16. This new version introduces advanced features aimed at providing nuisance alarm elimination and autonomous perimeter ...

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of KarXT or xanomeline and trospium chloride, in China.

On Monday, Leerink Partners initiated coverage on shares of PureTech Health (NASDAQ: PRTC), issuing an Outperform rating and setting a price target of $45.00. The biotechnology ...

You have permission to edit this article. Edit Close Newsletter Facebook ...

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad ...

(Alliance News) - PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. (Alliance News) - Stock prices in London opened somewhat ...

PureTech Health plc (Nasdaq ... led to the FDA approval of Cobenfy™ (formerly KarXT) for schizophrenia. With Glyph, we believe each of Seaport’s programs could create similar ...